New developments in immunosuppressive therapy in renal transplantation

Expert Opinion on Biological Therapy

Volumn 2, Issue 5, 2002, Pages 483-501

  Gourishankar, Sita ^a   Turner, Penny ^a   Halloran, Philip ^a  

^a Division of Nephrology   (Canada)

Author keywords

Cyclosporin; FK506; Immunosuppression; Mycophenolate mofetil; Renal transplant; Sirolimus

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BELATACEPT; CALCINEURIN INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOSPORIN; EVEROLIMUS; FINGOLIMOD; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; ISATX 247; LEFLUNOMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYCLONAL ANTIBODY; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; ANTIBODY; CALCINEURIN;

CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIFESPAN; REVIEW; ANIMAL; DRUG ANTAGONISM; IMMUNOLOGY; PASSIVE IMMUNIZATION; POLYOMA VIRUS;

ANIMAL; ANTIBODIES; ANTIBODIES, MONOCLONAL; CALCINEURIN; GRAFT REJECTION; HUMAN; IMMUNIZATION, PASSIVE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; POLYOMAVIRUS; SIROLIMUS; ANIMALS; HUMANS;

GLOMERULUS;

EID: 0035987403     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.5.483     Document Type: Review

References (156)

1. Improved graft survival after renal transplantation in the United States, 1988 to 1996
2. Call for revolution: A new approach to describing allograft deterioration
3. BK virus in solid organ transplant recipients: An emerging syndrome
4. Graft function and other risk factors as predictors of cardiovascular disease outcome
5. Mechanisms and consequences of arterial hypertension after renal transplantation
6. Arterial hypertension and renal allograft survival
7. Epidemiology of cardiovascular disease after renal transplantation
8. Proteinuria after renal transplantation affects not only graft survival but also patient survival
9. Hyperlipidemia and cardiovascular disease after organ transplantation
10. Cholesterol as an independent predictor of outcome after renal transplantation
11. Hyperlipidemia as a risk factor of renal allograft function impairment
12. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection
13. Immunosuppressive medications for renal transplantation: A multiple choice question
14. Drug-induced immunological tolerance
15. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance
16. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation
17. Cyclosporine A specifically inhibits function of nuclear proteins involved in T cell activation
18. Manipulating immune responses with immunosuppressive agents that target NFAT
19. Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription
20. Canadian Multicentre Transplant Study Group: A randomized clinical trial of cyclosporine in cadaveric renal transplantation
21. Outcome of cadaveric renal transplant patients treated for 10 years with cydosporine: Is chronic allograft nephropathy the major cause of late graft loss?
22. Long-term benefits and risks of cyclosporin A (Sandimmun) - An analysis at 10 years
23. Comparison of three immunosuppressive regimens in cadaver renal transplantation: Long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine
24. Relationship of pharmacokinetics to clinical outcomes
25. Use of C-2 monitoring to optimize cyclosporine microemulsion dosing in de novo renal transplant recipients: A safety analysis
26. A randomized, open-label, prospective study comparing two different cyclosporin A areas under the time-concentration curve for the prevention of rejection in renal transplantation
27. Evaluation of individual and combined neurotoxicity of the immunosuppressants cyclosporine and sirolimus by in vitro multinuclear NMR spectroscopy
28. The novel immunosuppressant SDZ-RAD protects rat brain slices from cyclosporine-induced reduction of high-energy phosphates
29. ISA(TX)247: A novel calcineurin inhibitor
30. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. A report of the European Tacrolimus Multicenter Renal Study Group
31. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
32. Tacrolimus (FK 506) in kidney transplantation: Five-year survival results of the U.S. multicenter, randomized, comparative trial
33. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients
34. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients
35. A prospective, randomized, multicentre study to compare the efficacy and safety of tacrolimus and cidosporin-microemulsion in renal transplantation
36. Neoral and tacrolimus are associated with a decrease in chronic allograft failure as compared with sandimmune
37. A meta-analysis of immunosuppression withdrawal trials in renal transplantation
38. Elective cyclosporine withdrawal after renal transplantation. A meta-analysis
39. Cyclosporin A withdrawal in live related renal transplantation: Long-term results
40. Elective cyclosporine withdrawal 1 year after renal transplantation
41. A prospective, randomised study of withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: 18 months follow-up data
42. Nephrotoxicity of calcineurin inhibitors: New therapeutic approaches
43. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
44. The impact of late acute rejection after cadaveric kidney transplantation
45. The inhibition of nucleic acid synthesis by mycophenolic acid
46. Purification, characterization and kinetic analysis of inosine-5'-monophosphate dehydrogenase of Trichomonas foetus
47. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
48. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: Results at three years
49. A placebo-controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-Year results
50. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection
51. Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation?
52. Conversion to mycophenolate mofetil in conjuction with stepwise withdrawal of cyclosporine in stable renal transplant recipients
53. Open randomised trial comparing a dual therapy regimen of MMF and corticosteroids with Neoral and corticosteroids for the prevention of rejection in renal allograft recipients
54. Enteric-coated mycophenolate sodium: Results of two pivotal global multicenter trials
55. Inhibition of crossmatch (CMX) positivity between donor/recipient pairs using intravenous gammaglobulin (IVIG) with subsequent transplantation
56. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection
57. Value of monoclonal antibody OKT3 in solid organ transplantation: A metaanalysis
58. A randomized prospective trial of OKT3 induction in the current immunosuppression era
59. The role of newer monoclonal antibodies in renal transplantation
60. Specific suppression of interleukin 2 biosynthesis by synthetic antisense oligodeoxynucleotides does not influence allograft rejection
61. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation
62. Regulatory CD4 T cells: Expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency Int
63. Natural CD4+ CD25+ regulatory T cells. Their role in the control of superantigen responses
64. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
65. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
66. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression
67. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation
68. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients
69. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation
70. Is it possible to reduce ciclosporine early with dacluzimab and mycophenolate mofetil in renal transplant recipients? Preliminary results in 169 patients of a randomized multicentric trial
71. Dacluzimab and mycophenolate mofetil allow for the use of low doses of tacrolimus and steroids in renal transplantation: A multi-center, pilot study in de novo renal transplantation
72. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection 1, 2
73. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression
74. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function
75. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function
76. Two dose dacluzimab (Zenapax) is safe and effective induction therapy in adult renal transplantation
77. Two doses of daduzimab are sufficient for prolonged IL-2R-alpha-chain blockade
78. The safety and efficacy of a two-dose dacluzimab induction regimen in renal transplant recipients
79. Economic analysis of basiliximab in renal transplantation
80. Basiliximab in the therapy of acute rejection after organ transplantation
81. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here?
82. Incidence and long-term cost of steroid-related side effects after renal transplantation
83. A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation
84. Long-term results with cyclosporine monotherapy in renal transplant patients: A multivariate analysis of risk factors
85. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
86. Rapid cortiscosteroid withdrawal in simultaneous pancreas-kidney (SPK) transplantation
87. Two-year insulin independence and metabolic follow-up after islet-alone transplantation in autoimmune diabetes
88. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol
89. Efficacy and safety of three months of tacrolimus/steroids/MMF followed by a controlled withdrawal of steroids or MMF: Results of a large, prospective, multicentre trial
90. Pravastatin improves long-term graft and patient survival after kidney transplantation - An examination of five-year follow-up data
91. Impact and management of hyperlipidemia posttransplantation
92. Use of angiotensinconverting enzyme inhibitors and angiotensin II antagonists in renal transplantation: Delaying the progression of allograft nephropathy?
93. ACE inhibitors and angiotensin II antagonists in renal transplantation: An analysis of safety and efficacy
94. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: A meta-analysis
95. Withdrawal of steroids after renal transplantation - Clinical predictors of outcome
96. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome
97. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts
98. North/South American, double-blind, parallel group study of the safety and efficacy of Certican™ (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral and corticosteroids
99. One year results of a multicenter, open-label trial on safety and efficacy of Certican™ (RAD) used in combination with Simulect, corticosteroids, and full or reduced dose Neoral in renal transplantation
100. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells
101. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study The Rapamune US Study Group
102. Immunosuppressive agents in organ transplantation: Past, present, and future
103. RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection
104. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
105. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografrs
106. Maintenance immunosuppression: New agents and persistent dilemmas
107. Sirolimus (Rapamune) maintenance therapy permits early cyclosporine withdrawal resulting in improved renal function: 12 Month results of the tri-continental trial
108. A prospective randomized trial of sirolimus vs. cyclosporine in kidney transplantation: Impact of calcineurin inhibitor elimination on renal function
109. Improved kidney graft function in patients receiving sirolimus, cyclosporine and steroids: The role of cyclosporine blood concentration
110. Improved renal function with cyclosporine elimination in sirolimustreated renal transplant recipients: One-year results from a phase II trial
111. Sirolimus and cyclosporin for renal transplantation
112. Comparison of sirolimus and mycophenolate mofetil on renal function and morphology in post-ischemic rat kidney
113. Sirolimus-tacrolim us combination immunosuppression
114. Two-year safety and efficacy of sirolimus in renal transplantation
115. Sirolimus-tacrolimus combination immunosuppression
116. FTY720: Mechanisms of action and its effect on organ transplantation
117. Fty720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo
118. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation
119. Human safety and pharmacology of FTY 720
120. Human pharmacokinetics of FTY 720
121. Safety and pharmacodynamics of multiple doses of FTY 720
122. FTY720 combined with Neoral and cordcosteroids is effective and safe in prevention of acute rejection in renal allograft recipients (interim data)
123. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study
124. European Leflunomide Study Group: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
125. Recent advances in immunosuppressive therapy for renal transplantation
126. Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide
127. Leflunomide and its analogue X920715 synergize with cyclosporin A in preventing early graft failure and delaying graft rejection of xenogeneic islets in non-obese diabetic mice
128. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation
129. The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses
130. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy
131. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection
132. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
133. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury
134. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand
135. Anti-B7-1 blocks mononuclear cell adherence in vasa recta after ischemia
136. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
137. Successful haploidentical bone marrow transplantation post ex vivo anergization of donor bone marrow alloreactive T cells
138. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
139. CD40L: A multi-functional ligand
140. X-linked immunodeficiency. The fruits of cooperation
141. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: Implications for tolerance induction
142. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients
143. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway
144. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates
145. Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys
146. Soluble intercellular adhesion molecule-1 (sICAM-1) after kidney transplantation: The origin and role of urinary sICAM-1?
147. Renal tubular cells express ICAM-1 during allograft rejection
148. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts
149. Adhesion molecules in rejection and tolerance of allografts
150. Protection against allograft rejection with intercellular adhesion molecule-1 oligodeoxynucleotides
151. Phase I/II safety-efficacy trial of intercellular adhesion molecule-1 (ICAM-1) antisense oligodeoxynucleotide (ISIS 2302) in the prevention of acute allograft rejection
152. A phase I/II trial of anti-CD11a monoclonal antibody in renal transplantation
153. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantation
154. Post-transplantation polyomavirus infections
155. Polyomavirus BK nephropathy in a kidney transplant recipient: Critical issues of diagnosis and management